<DOC>
	<DOCNO>NCT02377869</DOCNO>
	<brief_summary>Recently , novel assay detect heavy/light chain ( HLC ) ratio report enables improvement paraprotein detection monitor multiple myeloma plasma-cell dyscrasia . The prognostic biological role HLC assay yet study CLL . Aims propose study : 1 . To quantify analyze prognostic significance HLC ratio serum CLL patient . ( In addition FLC ) 2 . To study different pattern Immunoglobulin 's subclass antibody serum patient CLL compare healthy volunteer . 3 . To perform sub-analysis patient CLL autoimmune phenomenon ( AIHA ITP )</brief_summary>
	<brief_title>Heavy Light Chain Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Analysis immunoglobulin heavy/light chain pair In chronic lymphocytic leukemia Introduction Background : Chronic Lymphocytic Leukemia ( CLL ) common type leukemia western world . Median age diagnosis 72 year , male female ratio 2:1 . The disease characterize accumulation monoclonal mature B-cells co-express T-cell antigen CD5 , B-cell surface antigens CD19 , CD20 , CD23 ( 1 ) either kappa lambda immunoglobulin light chain restriction ( 2 ) . Diagnosis establish base IWCLL criterion publish Hallek al 2008 . ( 1 ) . CLL may heterogeneous clinical course wide spectrum manifestation range long live asymptomatic patient never require treatment rapid clinical course symptomatic progression . One remain important challenge CLL stratify patient different prognostic category , plan appropriate target therapy necessary . The important prognostic factor CLL relate presence typical genomic aberration leukemic cell ( 3 ) . Other essential prognostic parameter include : CD38 expression , presence ZAP-70 , immunoglobulin heavy chain mutational status , beta 2 microglobulin ( B2MG ) level . ( 1 ) . Patients CLL , 10 % risk develop autoimmune complication mostly auto-immune hemolytic anemia ( AIHA ) immune thrombocytopenia ( ITP ) ( 4-6 ) . The pathogenesis autoimmune cytopenia link production polyclonal immunoglobulin G ( IgG ) antibody ( less frequently IgM ) direct variety red blood cell platelet antigen . ( 4-6 ) . The use serum free light chain ( FLC ) level important prognostic tool different plasma cell dyscrasia already well establish ( 75 ) prognostic significance FLC CLL report recently publication ( 8-10 ) . Furthermore , Tsai et al , also describe serum FLC abnormality may precede diagnosis 38 % patient CLL ( 11 ) . Recently , novel assay detect heavy/light chain ( HLC ) ratio report enables improvement paraprotein detection monitor multiple myeloma plasma-cell dyscrasia . ( 12-13 ) . The prognostic biological role HLC assay yet study CLL . Aims propose study : 1 . To quantify analyze prognostic significance HLC ratio serum CLL patient . ( In addition FLC ) 2 . To study different pattern Immunoglobulin 's subclass antibody serum patient CLL compare healthy volunteer . 3 . To perform sub-analysis patient CLL autoimmune phenomenon ( AIHA ITP ) Materials method : The study perform collaboration Israeli CLL Study Group . All patient include complete clinical database available medical record summarize . Baseline laboratory parameter examine include : complete blood count , Coombs test , serum B2MG LDH , Immunoglobulin level , , flow-cytometry include CD38 expression ZAP70 urine Bence Jones protein . Frozen serum sample CLL patient analyzed level : - Free light chain : kappa/lambda , ratio K/L total sum K+L . - IgG1 , IgG2 , IgG3 , IgG4 . - Isoforms heavy/light chain IgG kappa , IgG lambda , IgA kappa , IgA lambda , IgM kappa , IgM lambda References : 1 . Michael Hallek , Bruce D. Cheson , Daniel Catovsky , et al . Guidelines diagnosis treatment chronic lymphocytic leukemia : report International Workshop Chronic Lymphocytic Leukemia update National Cancer Institute-Working Group 1996 guideline . Blood . Jun 15 , 2008 ; 111 ( 12 ) : 5446-5456 . 2 . Moreau EJ , Matutes E , A'Hern RP , et al . Improvement chronic lymphocytic leukemia score system monoclonal antibody SN8 ( CD79b ) . Am J Clin Pathol.1997 ; 108:378-382 . 3 . DÃ¶hner H , Stilgenbauer S , Benner A , et al . Genomic aberration survival chronic lymphocytic leukemia . N Engl J Med . 2000 Dec 28 ; 343 ( 26 ) :1910-6 . 4 . Hamblin TJ , Oscier DG , Young BJ . Autoimmunity chronic lymphocytic leukemia . J Clin Pathol 1986 ; 39 ; 713-16 5 . Zent CS , Kay NE . Autoimmune complication chronic lymphocytic leukaemia ( CLL ) . Best Pract Res Clin Haematol . 2010 Mar ; 23 ( 1 ) :47-59 . 6 . Visco C , Barcellini W , Maura F , Neri A , Cortelezzi A , Rodeghiero F. Autoimmune cytopenia chronic lymphocytic leukemia . Am J Hematol . 2014 Jun 10 7 . Dispenzieri A , Kyle R , Merlini G , et al . International Myeloma Working Group guideline serum-free light chain analysis multiple myeloma related disorder . Leukemia . 2009 Feb ; 23 ( 2 ) :215-24 . 8 . Maurer MJ , Cerhan JR , Katzmann JA , et al . Monoclonal polyclonal serum free light chain clinical outcome chronic lymphocytic leukemia . Blood . 2011 Sep 8 ; 118 ( 10 ) :2821-6 9 . Morabito F , De Filippi R , Laurenti L , et al . The cumulative amount serum-free light chain strong prognosticator chronic lymphocytic leukemia . Blood . 2011 Dec 8 ; 118 ( 24 ) :6353-61 . 10 . Sarris K , Maltezas D , Koulieris E , et al . Prognostic significance serum free light chain chronic lymphocytic leukemia . Adv Hematol . 2013 ; 2013:359071 11 . Tsai HT , Caporaso NE , Kyle RA , et al . Evidence serum immunoglobulin abnormality 9.8 year diagnosis chronic lymphocytic leukemia : prospective study . Blood . 2009 Dec 3 ; 114 ( 24 ) :4928-32 12 . Ludwig H , Milosavljevic D , Zojer N , et al . Immunoglobulin heavy/light chain ratio improve paraprotein detection monitoring , identify residual disease correlate survival multiple myeloma patient . Leukemia . 2013 Apr ; 27 ( 4 ) :996 . 13 . Katzmann JA , Clark R , Kyle RA , et al . Suppression uninvolved immunoglobulin define heavy/light chain pair suppression risk factor progression MGUS . Leukemia . 2013 Jan ; 27 ( 1 ) :208-12 .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>New diagnose patient CLL ( untreated ) Not treat immunoglobulin Not treat steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>